PL359563A1
(en)
*
|
2000-06-26 |
2004-08-23 |
Pfizer Products Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
|
AU2002340139A1
(en)
*
|
2001-10-09 |
2003-04-22 |
The University Of Cincinnati |
Inhibitors of the egf receptor for the treatment of thyroid cancer
|
NZ536513A
(en)
|
2002-05-16 |
2007-10-26 |
Novartis Ag |
Use of EDG receptor binding agents in cancer
|
ES2388138T3
(es)
|
2003-08-27 |
2012-10-09 |
Ophthotech Corporation |
Terapia de combinación para tratamiento de trastornos neovasculares oculares
|
BRPI0416909A
(pt)
*
|
2003-11-25 |
2007-01-16 |
Pfizer Prod Inc |
método de tratamento de aterosclerose
|
AR047470A1
(es)
*
|
2004-01-29 |
2006-01-18 |
Novartis Ag |
Derivados de pirrolo-pirimidina utiles para el tratamiento de enfermedades proliferativas,composiciones farmaceuticas que los contienen,y procesos para su preparacion
|
GB0403606D0
(en)
*
|
2004-02-18 |
2004-03-24 |
Novartis Ag |
Organic compounds
|
WO2005095419A1
(ja)
*
|
2004-04-01 |
2005-10-13 |
Takeda Pharmaceutial Company Limited |
チアゾロピリミジン誘導体
|
RS52545B
(en)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
INHIBITORI PROTEIN APOPTOZE (IAP)
|
MEP8409A
(en)
|
2004-06-02 |
2011-12-20 |
|
Fused heterocyclic compound
|
RU2007107167A
(ru)
*
|
2004-07-30 |
2008-09-10 |
Метилджин, Инк. (Ca) |
Ингибиторы передачи сигнала рецептора vegf и рецептора hgf
|
JO2596B1
(en)
*
|
2004-11-30 |
2011-02-27 |
نوفارتيس ايه جي |
Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
|
NZ555370A
(en)
|
2004-12-15 |
2010-03-26 |
Sigma Tau Ind Farmaceuti |
Combinations of therapeutic agents for treating cancer
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
JP2009502960A
(ja)
*
|
2005-07-27 |
2009-01-29 |
ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム |
膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
|
US20080227980A1
(en)
*
|
2005-08-05 |
2008-09-18 |
Novartis Ag |
Preparation of a 7H-Pyrrolo [2,3-D] Pyrimidine Derivative
|
KR20080071600A
(ko)
|
2005-11-21 |
2008-08-04 |
노파르티스 아게 |
Mtor 억제제를 사용하는 신경내분비 종양 치료법
|
KR20080095859A
(ko)
*
|
2006-01-23 |
2008-10-29 |
노파르티스 아게 |
고체 형태의 피롤로피리미딘 유도체 및 항종양제로서의그의 용도
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
US20090099103A1
(en)
*
|
2006-04-05 |
2009-04-16 |
Novartis Ag. |
Combinations of therapeutic agents for treating cancer
|
EP2606890A1
(en)
|
2006-04-05 |
2013-06-26 |
Novartis AG |
Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
|
MX2008012715A
(es)
|
2006-04-05 |
2008-10-14 |
Novartis Ag |
Combinaciones de agentes terapeuticos para el tratamiento de cancer.
|
CN101443002B
(zh)
|
2006-05-09 |
2012-03-21 |
诺瓦提斯公司 |
包含铁螯合剂和抗肿瘤药的组合及其用途
|
DE602007013441D1
(de)
|
2006-09-29 |
2011-05-05 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
MX2009004700A
(es)
*
|
2006-11-06 |
2009-05-15 |
Supergen Inc |
Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
|
EP2120900A2
(en)
|
2007-02-15 |
2009-11-25 |
Novartis AG |
Combination of lbh589 with other therapeutic agents for treating cancer
|
ES2424977T3
(es)
*
|
2007-08-08 |
2013-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
|
KR101673621B1
(ko)
|
2008-03-24 |
2016-11-07 |
노파르티스 아게 |
아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제
|
BRPI0909159A2
(pt)
|
2008-03-26 |
2015-11-24 |
Novartis Ag |
inibidores baseados em hidroxamato de desacetilases b
|
BRPI0917459B1
(pt)
|
2008-08-20 |
2017-09-12 |
Zoetis Services Llc |
N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
EP2391366B1
(en)
|
2009-01-29 |
2012-11-28 |
Novartis AG |
Substituted benzimidazoles for the treatment of astrocytomas
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
AU2010264698C1
(en)
|
2009-06-26 |
2013-05-16 |
Novartis Ag |
1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17
|
KR20120065321A
(ko)
*
|
2009-07-28 |
2012-06-20 |
우베 고산 가부시키가이샤 |
피롤로〔2,3-d〕피리미딘 유도체
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
EP2467141B1
(en)
|
2009-08-17 |
2018-10-31 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
EP2467383A1
(en)
|
2009-08-20 |
2012-06-27 |
Novartis AG |
Heterocyclic oxime compounds
|
JP2013503129A
(ja)
|
2009-08-26 |
2013-01-31 |
ノバルティス アーゲー |
テトラ−置換ヘテロアリール化合物ならびにmdm2および/またはmdm4モジュレーターとしてのそれらの使用
|
EA201200651A1
(ru)
|
2009-11-04 |
2012-12-28 |
Новартис Аг |
Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек
|
EA201200617A1
(ru)
|
2009-11-23 |
2012-11-30 |
Серулин Фарма Инк. |
Полимеры на основе циклодекстрина для доставки лекарственных средств
|
WO2011070030A1
(en)
|
2009-12-08 |
2011-06-16 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
DK2612151T3
(da)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
Biomarkører og fremgangsmåder til behandling
|
CN103108871B
(zh)
|
2010-09-16 |
2014-09-10 |
诺华股份有限公司 |
17α-羟化酶/C17,20-裂合酶抑制剂
|
CA2822565A1
(en)
|
2010-12-21 |
2012-06-28 |
Novartis Ag |
Bi-heteroaryl compounds as vps34 inhibitors
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
EP2678016B1
(en)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
ES2656218T3
(es)
|
2011-04-28 |
2018-02-26 |
Novartis Ag |
Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa
|
MX2013014398A
(es)
|
2011-06-09 |
2014-03-21 |
Novartis Ag |
Derivados de sulfonamida heterociclicos.
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
JP2014518256A
(ja)
|
2011-06-27 |
2014-07-28 |
ノバルティス アーゲー |
テトラヒドロ−ピリド−ピリミジン誘導体の固体形態および塩類
|
KR20140058543A
(ko)
*
|
2011-07-08 |
2014-05-14 |
노파르티스 아게 |
신규 피롤로 피리미딘 유도체
|
UY34329A
(es)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
Compuestos de triazolopiridina
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
AU2012356083B2
(en)
|
2011-12-22 |
2015-01-22 |
Novartis Ag |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
MX2014007730A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
KR20140107574A
(ko)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
JP2015503516A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Bcl2と結合相手の相互作用を阻害するための化合物
|
MX2014007732A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los mismos componentes de enlace.
|
WO2013096049A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
EP3964513A1
(en)
|
2012-04-03 |
2022-03-09 |
Novartis AG |
Combination products with tyrosine kinase inhibitors and their use
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN104321325B
(zh)
|
2012-05-24 |
2016-11-16 |
诺华股份有限公司 |
吡咯并吡咯烷酮化合物
|
CN104582732A
(zh)
|
2012-06-15 |
2015-04-29 |
布里格姆及妇女医院股份有限公司 |
治疗癌症的组合物及其制造方法
|
US9738643B2
(en)
|
2012-08-06 |
2017-08-22 |
Duke University |
Substituted indazoles for targeting Hsp90
|
US20150218173A1
(en)
|
2012-09-26 |
2015-08-06 |
Bayer Pharma Aktiengesellschaft |
Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
|
CA2885783A1
(en)
|
2012-09-26 |
2014-04-03 |
Bayer Pharma Aktiengesellschaft |
Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
|
CN102936251A
(zh)
*
|
2012-11-05 |
2013-02-20 |
上海毕得医药科技有限公司 |
一种吡咯并[2,3-d]嘧啶衍生物的制备方法
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
EP2948451B1
(en)
|
2013-01-22 |
2017-07-12 |
Novartis AG |
Substituted purinone compounds
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
CA2900097A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
JP2016516046A
(ja)
|
2013-03-14 |
2016-06-02 |
ジェネンテック, インコーポレイテッド |
がんの治療方法及びがん薬物耐性を阻止する方法
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
CN110193009A
(zh)
|
2013-07-12 |
2019-09-03 |
伊维希比奥公司 |
用于治疗或预防眼科病的方法
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
JP6494633B2
(ja)
|
2013-09-22 |
2019-04-03 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc |
置換されているアミノピリミジン化合物および使用方法
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
WO2015148714A1
(en)
|
2014-03-25 |
2015-10-01 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
CA2943979A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
KR20160132496A
(ko)
|
2014-04-03 |
2016-11-18 |
인빅터스 온콜로지 피비티. 엘티디. |
초분자 조합 치료제
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
CN108064274A
(zh)
|
2014-07-30 |
2018-05-22 |
耶达研究及发展有限公司 |
用于培养多能干细胞的培养基
|
RU2695230C2
(ru)
|
2014-07-31 |
2019-07-22 |
Новартис Аг |
Сочетанная терапия
|
JP2018527362A
(ja)
|
2015-09-11 |
2018-09-20 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. |
置換されたヘテロアリール化合物および使用方法
|
BR112018071592A8
(pt)
*
|
2016-04-19 |
2019-02-26 |
Univ California |
inibidores de erbb e usos dos mesmos
|
US11261187B2
(en)
|
2016-04-22 |
2022-03-01 |
Duke University |
Compounds and methods for targeting HSP90
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
KR20190101406A
(ko)
|
2016-12-23 |
2019-08-30 |
아비나스 오퍼레이션스, 인코포레이티드 |
Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법
|
JP7254076B2
(ja)
|
2017-11-19 |
2023-04-07 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
置換ヘテロアリール化合物及び使用方法
|
EP3730483B1
(en)
|
2017-12-21 |
2023-08-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
CA3083040A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
CN113874015B
(zh)
|
2018-12-21 |
2024-05-24 |
细胞基因公司 |
Ripk2的噻吩并吡啶抑制剂
|
EP3914698A1
(en)
|
2019-01-23 |
2021-12-01 |
Yeda Research and Development Co. Ltd |
Culture media for pluripotent stem cells
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
EP4192509A1
(en)
|
2020-08-05 |
2023-06-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
US11814388B1
(en)
|
2020-08-28 |
2023-11-14 |
Ferris State University |
Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers
|
US11999964B2
(en)
|
2020-08-28 |
2024-06-04 |
California Institute Of Technology |
Synthetic mammalian signaling circuits for robust cell population control
|
GB2617409A
(en)
|
2022-04-27 |
2023-10-11 |
Cancertain Ltd |
Method for predicting responsiveness to therapy
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024091370A1
(en)
*
|
2022-10-26 |
2024-05-02 |
Acerand Therapeutics (Usa) Limited |
5,6-fused bicyclic heteroaromatic compounds
|